At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 401 enrolled
Drug / intervention
Azelaic acid foam 15% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Study to Investigate Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily in Subjects With Papulopustular Rosacea
In Brief
A Phase 2 clinical trial evaluating Azelaic acid foam 15% and Vehicle foam for Papulopustular Rosacea. Completed, enrolled 401 participants across 20 sites.
Detailed Summary
This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPapulopustular Rosacea
CountriesUnited States
CollaboratorsBayer
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
First PostedDec 2009
Primary CompletionAug 2010
TodayJul 2026
First PostedDec 3, 2009
Enrollment StartDec 1, 2009
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.6 years ago
Interventions
Azelaic acid foam 15%drug
Applied topically twice daily for 12 weeks
Vehicle foamdrug
Applied topically twice daily for 12 weeks